Cairo March 13/2014

1. Partners in care to Improve Quality of LifeAbboud BejjaniVice President AbbVie Biopharmaceutical Cairo March 13/2014

2. Who I am? Degree… Vice President Middle East, Africa & Pakistan Consulting 15 Years!

3. AbbVie… Who We are? A leading global biopharmaceutical company one year old, but carrying 120 years history in research. AbbVie aspires to contribute to Healthcare Sustainability via Innovative Medicines and New Healthcare Solutions. (Chicago Based company)

4. AbbVie Way! Leading biopharmaceutical company in the life sciences industry that fosters pharma innovation & competitiveness a long-term, reliable Partner and a key contributor to the economy and healthcare sustainability • Responsibly active member of the community

5. AbbViePart of the Innovative Biopharmaceutical Industry • The innovative biopharmaceutical industry represents global leading pharmaceutical research and biotechnology companies • Our companies are devoted to discovering new medicines that allow patients to live longer, healthier, and more productive lives • In 2009, the biopharmaceutical sector invested approximately $65.3 billion in research and development

6. Biopharmaceutical Companies’Investment in R&D Increasing Steadily “ Total Biopharmaceutical Company R&D and PhRMA Member R&D: 1995–20081 The pharmaceutical industry is one of the most research-intensive industries in the United States. Pharmaceutical firms invest as much asfive times more in research and development, relative to their sales, than the average U.S. manufacturing firm.2 — Congressional Budget Office “ Sources: 1Burrill & Company, analysis for PhRMA, 2005–2009; Pharmaceutical Research and Manufacturers of America, PhRMA Annual Member Survey (Washington, DC: PhRMA, 1981-2009); 2CBO, Research and Development in the Pharmaceutical Industry, 2006.

7. AbbVie Leading Therapeutical Areas & Research Focus • Immunology • Rheumatoid Arthritis • Ankylosing Spondylitis • Psoriasis • Crohn’s Disease • Neonatology (preterm babies) • Anesthesia • Antiviral (HIV/HCV) • Renal Disease • Central Nervous System • Oncology

8. AbbVie & The Arab World Long Term Relation Ship Can we Partner ? Over 60 years of PartnerShip! FOCUS Partners in care to Improve Quality of Life

9. Health Authorities’ Objectives Objective How Consequence By Improving Longevity and Quality of Life Higher Quality Care Manage rising Healthcare costs By Widening Access To Care

10. How we can help? • Technology and knowledge transfer Improve patient access to innovative medicines and as results improve patient outcomes Improve efficiency of healthcare delivery Anticipate in boosting the economy by local investments Create high quality jobs

11. Improve patient access to innovative medicines and as results improve patient outcomes • Prescription medicines play a major role in saving and improving lives • Over the last 25 years, prescription medicines have significantly reduced deaths from major diseases such as heart disease, several cancers, and HIV /AIDS • Improved the quality of lives of people suffering from conditions such as arthritis disease. Currently we are talking about full remission from Many Immune Diseases such as Crohn’s, Rheumatoid Arthritis, Psoriasis, Parkinson, needless to mention the prematurity solutions for babies…etc… • Recent advances include a new generation of personalized medicines, treatment for some rare diseases and cure for infections like Hepatitis C.

12. Major Advances in Treatment and Prevention Since 1980 life expectancy for cancer patients has increased by 3 years. Research finds that medicines alone account for 50-60% of survival increases. Thanks in part to new medicines, heart failure and heart attack deaths fell by 45% in just the last decade. Within three years of introduction of the first antiretroviral treatments, HIV/AIDS deaths dropped by nearly 70%. “The rapid increases that have been observed in drug-related R&D spending have been accompanied by major therapeutic gains in available drug treatments.” CBO, 2006 12

13. HIV/AIDS: Decline in Death rates

14. U.S. Life Expectancy 1950-2007

15. How we can help? • Technology and knowledge transfer Improve patient access to innovative medicines and as results improve patient outcomes Improve efficiency of healthcare delivery Anticipate in boosting the economy by local investments Create high quality jobs

16. Improving Efficiency of Healthcare Delivery • Efficient management of Non Communicable Diseases through : • Health education • Disease management programs • Patient screening programs • Eradication of communicable diseases • Early introduction of innovative therapeutic options • Continuous medical education of HCP • Training of healthcare professionals

17. Some Real Life Examples of Health Education–IMID Congress • IMID – Immune Mediated Inflammatory Disorders Congress5% -7% MEA population is afflicted • Treated and managed by multi-specialists like Rheumatologists, Dermatologists, Gastroenterologists, Ophthalmologists and Internists who have little time and opportunity to communicate with each other. • IMID Congress created a multispecialty platform to bring these specialists together to discuss the latest developments and research to achieve improved patient outcomes. Result: Increased referrals of patients across the specialties that facilitates better co-management of patients.

18. Improving Efficiency of Healthcare Delivery • Efficient management of Non Communicable Diseases through : • Health education • Disease management programs • Patient screening programs • Eradication of communicable diseases • Early introduction of innovative therapeutic options • Continuous medical education of HCP • Training of healthcare professionals • Public Awareness

19. Some Real Life Examples of what we did –Academy of Imaging • AbbVie partnered with GENERAL Electric to support continuous education of Rheumatologists who were interested in learning ultrasound of the joints. This education was the first of its kind in the MEA and helped to improve the standard of care of the RA patients and support the physician in diagnosis and monitoring of the disease. • Result: Rheumatologists started using US in practice and ultrasound became increasingly recognized as a standard tool for diagnosing and treating the aggressive disease early.

20. Improving Efficiency of Healthcare Delivery • Efficient management of Non Communicable Diseases through : • Health education • Disease management programs • Patient screening programs • Eradication of communicable diseases • Early introduction of innovative therapeutic options • Continuous medical education of HCP • Training of healthcare professionals • Public Awareness

21. Some Real Life Examples of what we did –Patient Support Program • Patient Support Specialists (trained physicians and pharmacists by qualification) educate patients on disease understanding and elevate awareness on possible detrimental outcomes if left untreated. • In addition: • Organize patients’ days whereby consultants are • invited to educate patients • Advise patients to follow up with Physiotherapists • Organize meetings of patients with Nutritionists to learn about optimal diet regime. • Facilitate appointment with Psychiatrists for the depressed Ps patients if needed • The program is endorsed by MOH and Health Authorities • Received endorsement of the Her Royal Highness Princess Oraib Al Saud (daughter of HH Saudi King) to endorse a valuable program aimed to raise prematurity awareness and to call for action to set the healthcare standards of Neonatology in Saudi. • The program is supported by many other corporate partners.

22. How we can help? • Technology and knowledge transfer Improve patient access to innovative medicines and as results improve patient outcomes Improve efficiency of healthcare delivery Anticipate in boosting the economy by local investments Create high quality jobs

23. Health Authorities’ Objectives Objective How Consequence Improve Longevity and Quality of Life Higher Quality Care Manage rising Healthcare costs Wider Access To Care

24. How we can help?

25. PPP: Elements of Success ! Open Dialogue Transparency Trust

26. What is required from our side! Better Understanding of your challenges Open Dialogue More discussion Don’t be afraid! Transparency Trust Show what we do

27. What we like you to do! Better Understanding of our challenges Open Dialogue Open hears for Pharma Economics Discussion Transparency Trust Pharma As a Cost component of Health Bill

28. What we like you to do! Better Understanding of our challenges Open Dialogue Open hears for Pharma Economics Discussion Transparency Trust Pharma As a Cost component of Health Bill

29. Industry Concern : Valuable But Vulnerable Limitless Challenge Opportunities Growing 29

30. DO YOU KNOW?? Post-MarketingSurveillance Drug Discovery Preclinical Clinical Trials FDA Review Scale-Up to Mfg. ~ 5,000 – 10,000 250 5 COMPOUNDS ONE FDA-APPROVED DRUG PRE-DISCOVERY PHASE 3 PHASE 1 PHASE 2 NDA SUBMITTED IND SUBMITTED NUMBER OF VOLUNTEERS 20–100 100–500 1,000–5,000 0.5 – 2 YEARS INDEFINITE 3 – 6 YEARS 6 – 7 YEARS Developing a new medicine is lengthy, risky, and costly. New drug development takes an average of 10–15 years, and costs approx. US $1.3 billion. 30 Sources: Drug Discovery and Development: Understanding the R&D Process,www.innovation.org

31. Do you know?? Cost to Develop One New Drug Billions 31

32. Successfully Approved Commercial Medecines

33. What we like you to do! Better Understanding of our challenges Open Dialogue Open hears for Pharma Economics Discussion Transparency Trust Pharma As a Cost component of Health Bill

34. Medicines can Result in Extraordinary Savings for Patients and Health Systems In the U.S., for example, each prescription saves US $57 in avoidable hospital costs. Diabetes: $1 more spent on diabetes medicines = US $7.10 less spent on other services. High Blood Pressure: In 2002, antihypertensives prevented 833,000 stroke and heart attack hospitalizations, saving US $16.5 billion in medical costs. Asthma: A 10% increase in adherence to asthma medicines in elderly patients leads to a 5% decrease in total annual medical spending. Medicines can reduce health costs by preventing and managing disease Sources: Sources: B.C. Stuart, et al. ”Assessing the Impact of Drug Use on Hospital Costs.”Health Services Research, February 2009; M.C. Sokol, K.A. McGuigan, R.R. Verbrugge, R.S. Epstein, “Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost,” Medical Care, 43 (2005): 6, 521-530; D. Cutler, et al., “The Value of Antihypertensive Drugs: A Perspective on Medical Innovation,” Health Affairs, January/February, 2007; B. Briesacher, et al. “Consequences of Poor Compliance with Biphosphonates,” Bone, 2007. R. Balkrishnan, et al., “Self-Reported Health Status, Prophylactic Medication Use, and Healthcare Costs in Older Adults with Asthma,: Journal of the American Geriatric Society, 2002.

35. What we like you to do! Better Understanding of our challenges Open Dialogue Open hears for Pharma Economics Discussion Transparency Trust Pharma As a Cost component of Health Bill

36. Medicines and Health Spending Growth

37. We need Common understanding! Common Interest and Better understanding of each other needs Open Dialogue Transparency Trust

38. Improving Patients’ Health and Quality of Life “New drugs allow children with rheumatoid arthritis to walk and to go to school. New drugs shrink cancerous tumors and they control the advance of HIV. They prevent or halt heart disease, slow the progression of multiple sclerosis, and cure infectious diseases.” 13 —Mark B. McClellan, M.D., Ph.D., Then-FDA Commissioner, September 2003

39. YES WE ARE PARTNERS!!! Partners in care to Improve Quality of Life

40. THANK YOU